New approaches to mUC treatment in 2024
EVENT DETAILS
ACCREDITATION
Speakers: Normand Blais & Srikala Sridhar
OBJECTIVES
By participating in this learning program, healthcare providers can expect to:
- Discuss general statistics around bladder cancer and recent changes to the staging system.
- Define who is eligible for cisplatin, carboplatin, and/or EV+P
- How do we approach a 1L la/mUC treatment in 2024
- How do we manage node positive disease
- What are future directions in the field?